Stay updated on Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial
Sign up to get notified when there's something new on the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page.

Latest updates to the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added, replacing v3.4.1. A funding/operating-status notice was removed; these updates pertain to site-wide notices rather than the study record content.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding notice and a new Revision: v3.4.1. The previous Revision: v3.4.0 entry was removed.SummaryDifference0.5%

- Check28 days agoChange DetectedThe history page now uses green and red highlights to indicate additions and deletions, and includes a glossary display option. The revision label has been updated to v3.4.0.SummaryDifference0.7%

- Check64 days agoChange DetectedFooter updates show Revision: v3.3.3 and the HHS Vulnerability Disclosure link was removed. The rest of the page content and study history remain unchanged.SummaryDifference0.1%

- Check85 days agoChange DetectedA new revision entry v3.3.2 is added to the history and the previous v3.3.1 entry is removed.SummaryDifference0.1%

- Check92 days agoChange DetectedThe latest history shows a new entry Revision: v3.3.1 added and Revision: v3.2.0 removed, reflecting a minor page revision. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page.